Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of MDM2 (green) in HeLa cells either left untreated (left panel) or treated with 50nM Nocodazole (right panel) for 16 hours. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature and blocked with 3% Blocker BSA (Product # 37525) for 15 minutes at room temperature. Cells were probed with a MDM2 monoclonal antibody (Product # MA1-113) at a concentration of 1ug/ml for at least 1 hour at room temperature, washed with PBS, and incubated with a Goat anti-Mouse IgG (H+L) Superclonal Secondary Antibody, Alexa Fluor 488 conjugate (Product # A28175) at a dilution of 1:400 for 30 minutes at room temperature. Actin (red) was stained with DyLight 554 Phalloidin (Product # 21834) and nuclei (blue) were stained with Hoechst 33342 dye (Product # 62249). Images were taken on a Thermo Scientific ArrayScan or ToxInsight Instrument at 20X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Storage buffer||PBS, pH 7.2-7.4, with 1mg/ml BSA, 30% glycerol|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||1-5 µg/ml|
|Immunofluorescence (IF)||1 - 5 µg/ml|
|Immunohistochemistry (Frozen) (IHC (F))||1 - 5 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||1:10-1:500|
|Immunoprecipitation (IP)||1 - 5 µg/ml|
|Western Blot (WB)||0.5-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody recognizes the ~90 kDa (apparent MW) MDM2 protein. Also recognizes isoforms at ~57 and ~74/76 kDa.
This antibody was originally validated as part of a Thermo Scientific Cellomics High Content Screening Kit. The antibody sold separately may have slightly different performance and may need to be further optimized for the best results.
This gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report.
MA1-113 was used in immunohistochemistry - paraffin section to characterize a primary myxoid liposarcoma with chondroid and osseous components
|Weingertner N,Neuville A,Chibon F,Ray-Coquard I,Marcellin L,Ghnassia JP||Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry (23:230)||2015|
MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
MA1-113 was used in immunohistochemistry (paraffin) to discuss markers that distinguish between different subtypes of osteosarcomas.
|Yoshida A,Ushiku T,Motoi T,Beppu Y,Fukayama M,Tsuda H,Shibata T||The American journal of surgical pathology (36:423)||2012|
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
MA1-113 was used in immunohistochemistry to examine expression of MDM2-CDK4 in low-grade osteosarcomas and fibrous or fibro-osseous lesions of the bone or paraosseous soft tissue.
|Dujardin F,Binh MB,Bouvier C,Gomez-Brouchet A,Larousserie F,Muret Ad,Louis-Brennetot C,Aurias A,Coindre JM,Guillou L,Pedeutour F,Duval H,Collin C,de Pinieux G||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (24:624)||2011|
Anti-Murine Double Minute Chromosome-2; Anti-p53 Binding Protein; Anti-Ubiquitin Protein Ligase; double minute 2, human homolog of; p53-binding protein; MDM2 oncogene, E3 ubiquitin protein ligase; MDM2 proto-oncogene, E3 ubiquitin protein ligase; Mdm2, p53 E3 ubiquitin protein ligase homolog; Mdm2, transformed 3T3 cell double minute 2, p53 binding protein; oncoprotein Mdm2
ACTFS; hdm2; HDMX; MDM2